Australian biotech market watch 03/06/09
Wednesday, 03 June, 2009
After a few days of strong trading, buoyed by improving market optimism, the All Ordinaries is up 1.6%, although the majority of the gains was to be found in the finance and industrial sectors, with health only nudging 0.3% into the positive.
Cochlear (ASX:COH) is up 85c to $55.45. Earlier today, it was announced that Watpac (ASX:WTP) has been awarded the contract to construct the new global headquarters for Cochlear, to be located in the new Hearing Precinct of Sydney's Macquarie University.
Ramsay Health Care (ASX:RHC) rose 5% to $4.75 after a few days of declining prices.
Compumedics (ASX:CMP) is also up over 20% after it was announced it had received the Powerhouse Museum Award 2009 for design for Grael, its sleep diagnostics and recording system.
Other health care and biotechnology stocks were flat or inline with the general market trend.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
